BriaCell Therapeutics Announces Pricing of Offering

BriaCell Therapeutics (Nasdaq:BCTX) priced a best-efforts offering of 1,449,300 common shares at $3.25 per share, for expected gross proceeds of about $4.7 million before fees.

Rhea-AI Summary

BriaCell Therapeutics (Nasdaq:BCTX) priced a best-efforts offering of 1,449,300 common shares at $3.25 per share, for expected gross proceeds of about $4.7 million before fees. Closing is expected on June 2, 2026, subject to customary conditions.

Net proceeds are intended for working capital, general corporate purposes, and advancing business objectives. ThinkEquity is sole placement agent. The offering uses BriaCell’s effective Form S-3 shelf registration.

Positive

• Equity financing expected to raise approximately $4.7 million gross
• Proceeds allocated to working capital and business advancement
• Offering conducted under an already effective Form S-3 shelf
• Best-efforts offering fully comprised of primary shares by the company

Negative

• New common share issuance implies equity dilution for existing holders
• Best-efforts structure provides no firm commitment to place all shares
• Gross proceeds are before placement fees and offering expenses, reducing net cash received

Argus Jun 1 session

-9.07% close to close Open Argus

Details

News Market Reaction – BCTX

In the Jun 1 session, BCTX declined 9.07%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved -9.1% in the session following this news. A negative reaction despite this routine f...

Analysis

The stock moved -9.1% in the session following this news. A negative reaction despite this routine financing fits prior patterns, where five recent offerings produced an average move of -18.44%. Shares were already below the $7.04 200‑day average and far from the $36.90 52‑week high, so further weakness could reflect investor sensitivity to dilution and past going‑concern language rather than any change in the clinical outlook.

Key Figures

Shares Offered: 1,449,300 common shares Offering Price: $3.25 per share Gross Proceeds: approximately $4.7 million +4 more

Shares Offered

1,449,300 common shares

Best-efforts offering size

Offering Price

$3.25 per share

Pricing of new common shares

Gross Proceeds

approximately $4.7 million

Total gross proceeds before fees

Expected Closing Date

June 2, 2026

Scheduled closing of offering

Form Type

Form S-3 (File No. 333-276650)

Registration statement used for this offering

S-3 Filing Date

January 22, 2024

Date S-3 was filed with SEC

S-3 Effective Date

January 31, 2024

Date S-3 declared effective by SEC

Previous Offering Reports

5 past events · Latest: Jul 16

Same Type 5 events

1. Jul 16

   Offering closing

   24h Move

   +1.1%

   Closed $15M unit offering with warrants at $1.25 per unit.

2. Jul 15

   Offering pricing

   24h Move

   -61.8%

   Priced $15M public offering of 12M units with warrants.

3. Apr 28

   Offering closing

   24h Move

   -8.2%

   Closed $13.8M unit offering at $4.50 with $5.25 warrants.

4. Apr 24

   Offering pricing

   24h Move

   -13.8%

   Priced $13.8M public unit offering at $4.50 with warrants.

5. Feb 05

   Offering closing

   24h Move

   -9.6%

   Closed best-efforts offering of 762,500 shares for $3.05M.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

best-efforts offering, shelf registration statement, form s-3, prospectus supplement

4 terms

best-efforts offering financial

"announced the pricing of a best-efforts offering of 1,449,300 common shares."

A best-efforts offering is a way of selling new securities where the broker or underwriter agrees to try to sell as many shares or bonds as possible but does not promise to buy any unsold portion. For investors, it matters because the issuer bears the risk of weak demand — the deal may raise less money or the price may be more volatile, similar to hiring a salesperson who will try hard to sell your goods but won’t guarantee any specific sales.

shelf registration statement regulatory

"pursuant to a shelf registration statement on Form S-3 (File No. 333-276650)"

A shelf registration statement is a document a company files with regulators that allows it to sell shares or bonds quickly when it’s a good time to raise money. It’s like having a pre-approved plan ready so the company can act fast without going through lengthy paperwork each time they want to sell, making fundraising more flexible.

form s-3 regulatory

"registration statement on Form S-3 (File No. 333-276650), including a base prospectus"

Form S-3 is a legal document companies use to register their stock sales with the government, making it easier and faster for them to raise money by selling shares to investors. It’s like having a pre-approved shopping list that lets a company quickly sell new shares when they need funds, without going through a lengthy approval process each time.

prospectus supplement regulatory

"A final prospectus supplement and accompanying prospectus relating to the offering"

A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

PHILADELPHIA and VANCOUVER, British Columbia, May 31, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced the pricing of a best-efforts offering of 1,449,300 common shares. Each common share is being sold at an offering price of $3.25 per share. All of the common shares in the offering are being offered by the Company. Total gross proceeds from the offering, before deducting placement agent’s fees and other offering expenses, are expected to be approximately $4.7 million. The offering is expected to close on June 2, 2026, subject to satisfaction of customary closing conditions. The Company is relying upon the exemption set forth in Section 602.1 of the TSX Company Manual, which provides that the TSX will not apply its standards to certain transactions involving eligible interlisted issuers on a recognized exchange, such as Nasdaq.

The Company intends to use the net proceeds from the offering for working capital requirements, general corporate purposes, and the advancement of business objectives.

ThinkEquity is acting as sole placement agent for the offering.

The securities described above are being offered and sold by the Company pursuant to a shelf registration statement on Form S-3 (File No. 333-276650), including a base prospectus, filed with the U.S. Securities and Exchange Commission (the “SEC”) on January 22, 2024 and declared effective on January 31, 2024. The offering is being made only by means of a written prospectus. A final prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and can be accessed for free on the SEC’s website at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may be obtained, when available, from the offices of ThinkEquity, 17 State Street, 41^st Floor, New York, New York 10004.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About BriaCell Therapeutics Corp.

BriaCell is an immuno-oncology-focused biotechnology company developing targeted and effective approaches for the management of cancer. More information is available at https://briacell.com/.

Forward-Looking Statements
This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on BriaCell’s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading "Risk Factors" in the Company's most recent Annual Report on Form 10-K, and under “Risks and Uncertainties” in the Company's other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under the Company's profiles on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law.

Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information

Company Contact:
William V. Williams, MD
President & CEO
1-888-485-6340
info@briacell.com 

Investor Relations Contact:
investors@briacell.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What are the key details of BriaCell’s (NASDAQ:BCTX) May 31, 2026 stock offering?

BriaCell priced a best-efforts offering of 1,449,300 common shares at $3.25 each. According to BriaCell, expected gross proceeds are about $4.7 million before placement agent fees and expenses, with all shares issued directly by the company.

When is BriaCell’s (BCTX) new share offering expected to close?

The offering is expected to close on June 2, 2026. According to BriaCell, closing remains subject to satisfaction of customary conditions, meaning timing and completion are not guaranteed and depend on standard regulatory and transactional requirements.

How will BriaCell (NASDAQ:BCTX) use the proceeds from the 2026 equity offering?

BriaCell plans to use net proceeds for working capital, general corporate purposes, and advancing business objectives. According to BriaCell, these funds are intended to support ongoing operations and strategic priorities rather than a specified acquisition or single project.

What is the impact of BriaCell’s May 2026 share sale on existing BCTX shareholders?

Issuing 1,449,300 new common shares will dilute existing shareholders’ ownership percentages. According to BriaCell, the trade-off is additional capital of about $4.7 million gross to fund working capital, corporate needs, and advancement of business objectives.

Under which registration statement is BriaCell’s (BCTX) 2026 offering being conducted?

The offering uses BriaCell’s Form S-3 shelf registration statement, File No. 333-276650. According to BriaCell, this shelf was filed January 22, 2024 and declared effective January 31, 2024, enabling timely issuance via a prospectus supplement.

Who is the placement agent for BriaCell’s May 31, 2026 stock offering (BCTX)?

ThinkEquity is acting as sole placement agent for the best-efforts offering. According to BriaCell, investors can obtain the final prospectus supplement and accompanying prospectus from ThinkEquity once available, or access the documents for free on the SEC’s website.